Alkermes plc Announces CEO Succession Plan February 25, 2026 — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes’ Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors —
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 February 25, 2026 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast [...]
Almirall’s 2025 Results February 23, 2026 Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory. This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM). The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch. Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists. Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China. Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.
FICO UK Credit Card Market Report: December 2025 February 17, 2026 Continued financial pressures evident as balances reach highest level since FICO records began
AB InBev Reports Full Year and Fourth Quarter 2025 Results February 12, 2026 Underlying EPS increased by 6% with continued margin expansion and free cash flow generation of 11.3 billion USD
Mastek Expands Leeds Office, Strengthening AI-Led Innovation and Long-Term Commitment to the UK February 11, 2026 Mastek (UK) Limited, a trusted AI first digital engineering and cloud transformation partner, announced the expansion of its Leeds office, marking a significant milestone in the company’s continued investment in the UK and its long-standing presence in the North of England. The expanded office was officially opened by Abhishek Singhh, President UKI & EU, Mastek, [...]
SheltonAI Announces Global Expansion, Senior Leadership Appointments, and Accelerated Growth February 9, 2026 SheltonAI, the institutional AI platform for valuation, announced senior executive appointments, major global expansion, and strong growth momentum entering 2026. SheltonAI announced several senior leadership appointments, including: Stephen Can, CSO, previously Executive Chairman & Founder of Blackstone Strategic Partners Peter Song, COO, previously COO of Blackstone Strategic Partners Chris Cooper, CFO, previously Global CFO at [...]
Airspan Networks Enters 2026 with Strong Growth and Profitability February 9, 2026 Strong and expanding Market Adoption across In-Building, Open RAN, and Air-to-Ground
Real Chemistry Strengthens Global Presence with New International Leadership Appointments and Expanded Regional Hubs February 5, 2026 Latest investment marks key milestone in the company’s global growth strategy, supporting clients across an increasingly complex healthcare landscape
Quantum Motion Expands Global Presence by Opening European Offices in Spain February 5, 2026 Quantum Motion today announced the opening of its offices in Spain, establishing a permanent base for quantum system development, integration and deployment in the European Union. The new site, which is located in the newly inaugurated nanoGUNE Quantum Tower, supports Quantum Motion’s scale-up of silicon-based quantum computing systems and strengthens the collaboration across Europe’s semiconductor, [...]